Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Employment agrmnt
OptimizeRx Corp (OPRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/06/2023 4 Odence-Ford Marion (General Counsel and CCO) has filed a Form 4 on OptimizeRx Corp
Txns: Paid exercise price by delivering 1,952 shares @ $7.06, valued at $13.8k
Exercised 6,649 restricted stock units @ $0
10/06/2023 4 Silvestro Stephen L (Chief Commercial Officer) has filed a Form 4 on OptimizeRx Corp
Txns: Paid exercise price by delivering 1,952 shares @ $7.06, valued at $13.8k
Exercised 6,649 restricted stock units @ $0
10/06/2023 4 Stelmakh Edward (CFO/COO) has filed a Form 4 on OptimizeRx Corp
Txns: Paid exercise price by delivering 4,117 shares @ $7.06, valued at $29.1k
Exercised 16,662 restricted stock units @ $0
10/06/2023 4 Besch Doug (Chief Product Officer) has filed a Form 4 on OptimizeRx Corp
Txns: Paid exercise price by delivering 976 shares @ $7.06, valued at $6.9k
Exercised 3,324 restricted stock units @ $0
08/18/2023 4 HALAS GUS D (Director) has filed a Form 4 on OptimizeRx Corp
Txns: Exercised 4,637 restricted stock units @ $0
Granted 10,061 restricted stock units @ $0
08/18/2023 4 Spangler Patrick D (Director) has filed a Form 4 on OptimizeRx Corp
Txns: Exercised 4,637 restricted stock units @ $0
Granted 10,061 restricted stock units @ $0
08/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/18/2023 4 WASSON GREGORY D (Director) has filed a Form 4 on OptimizeRx Corp
Txns: Exercised 4,637 restricted stock units @ $0
Granted 10,061 restricted stock units @ $0
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "OptimizeRx Reports Second Quarter 2023 Financial Results"
06/09/2023 SC 13G First Light Asset Management, LLC reports a 10.3% stake in OptimizeRx Corporation
06/07/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "OptimizeRx Reports First Quarter 2023 Financial Results - Total revenue of $13.0 million - GAAP net loss per share of $ - Non-GAAP net loss per share of $ ROCHESTER, Mich. – May 10, 2023 – OptimizeRx Corp. , a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the three months ended March 31, 2023. Quarterly comparisons are to the same year-ago period."
04/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/06/2023 SC 13G/A BlackRock Inc. reports a 6.1% stake in OPTIMIZERX CORP
04/03/2023 4 Lang James Paul (Director) has filed a Form 4 on OptimizeRx Corp
Txns: Exercised 657 restricted stock units @ $0
04/03/2023 4 HALAS GUS D (Director) has filed a Form 4 on OptimizeRx Corp
Txns: Exercised 657 restricted stock units @ $0
04/03/2023 4 WASSON GREGORY D (Director) has filed a Form 4 on OptimizeRx Corp
Txns: Exercised 657 restricted stock units @ $0
04/03/2023 4 Spangler Patrick D (Director) has filed a Form 4 on OptimizeRx Corp
Txns: Exercised 657 restricted stock units @ $0
04/03/2023 4 Vos Ellen O'Connor (Director) has filed a Form 4 on OptimizeRx Corp
Txns: Exercised 657 restricted stock units @ $0
03/14/2023 8-K Other Events  Interactive Data
03/10/2023 10-K Annual Report for the period ended December 31, 2022
03/10/2023 10-Q/A Quarterly Report for the period ended September 30, 2022 [amend]
03/10/2023 10-Q/A Quarterly Report for the period ended June 30, 2022 [amend]
03/10/2023 10-Q/A Quarterly Report for the period ended March 31, 2022 [amend]
03/10/2023 10-K/A Annual Report for the period ended December 31, 2021 [amend]
03/08/2023 8-K Quarterly results
Docs: "OptimizeRx Reports Fourth Quarter and Full Year 2022 Financial Results - Q4 revenue of $19.7 million, down 3% year-over-year and up 30% quarter-over-quarter - Q4 gross profit increased 1% year-over-year to $12.5 million as gross margins increased from 61% to 63% - Generated $10.7 million in cash flow from operations in 2022 - Repurchased 1.2 million shares during 2022 at an average price of $16.49 per share - Exited 2022 with six Real-World Data Artificial Intelligence deals ROCHESTER, Mich. – March 8, 2023 – OptimizeRx Corp. , a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the fourth quarter and full year ended December 31, 2022. Twelve Months Ended December 31, Key Performance Indicators * 2022 2021 Average revenu..."
02/14/2023 4 Odence-Ford Marion (General Counsel and CCO) has filed a Form 4 on OptimizeRx Corp
Txns: Paid exercise price by delivering 1,422 shares @ $17.34, valued at $24.7k
Exercised 4,000 restricted stock units @ $0
01/31/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/04/2023 4 HALAS GUS D (Director) has filed a Form 4 on OptimizeRx Corp
Txns: Exercised 409 restricted stock units @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy